Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Younger

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Cancer|June 5, 2003
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinomaJohanna C Bendell, Susan M Domchek, Harold J Burstein, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 11, 2008
Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamidePaul J Hesketh, Jerry Younger, Pedro Sanz-Altamira, et al.
Cancer|August 7, 2009
The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer deathL Leon Chen, Matthew E Nolan, Melvin J Silverstein, et al.
Cancer|August 12, 2009
Why cancer at the primary site and in the lymph nodes contributes to the risk of cancer deathJames S Michaelson, L Leon Chen, Melvin J Silverstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast CancerNeelima Vidula, Andrzej Niemierko, Giuliana Malvarosa, et al.
The International Journal of Biological Markers|September 28, 2012
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapyRimoun R Boutrus, Rita F Abi Raad, Irene Kuter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapyHarold J Burstein, Yu-Hui Chen, Leroy M Parker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapyHarold J Burstein, Leroy M Parker, Aparna Keshaviah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2019
<i>FGFR1</i> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR<sup>+</sup>) Breast CancerJoshua Z Drago, Luigi Formisano, Dejan Juric, et al.
Breast Cancer Research : BCR|December 1, 2020
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastasesJose Pablo Leone, Kyrre E Emblem, Michelle Weitz, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Cancer|June 5, 2003
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinomaJohanna C Bendell, Susan M Domchek, Harold J Burstein, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 11, 2008
Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamidePaul J Hesketh, Jerry Younger, Pedro Sanz-Altamira, et al.
Cancer|August 7, 2009
The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer deathL Leon Chen, Matthew E Nolan, Melvin J Silverstein, et al.
Cancer|August 12, 2009
Why cancer at the primary site and in the lymph nodes contributes to the risk of cancer deathJames S Michaelson, L Leon Chen, Melvin J Silverstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast CancerNeelima Vidula, Andrzej Niemierko, Giuliana Malvarosa, et al.
The International Journal of Biological Markers|September 28, 2012
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapyRimoun R Boutrus, Rita F Abi Raad, Irene Kuter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapyHarold J Burstein, Yu-Hui Chen, Leroy M Parker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapyHarold J Burstein, Leroy M Parker, Aparna Keshaviah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2019
<i>FGFR1</i> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR<sup>+</sup>) Breast CancerJoshua Z Drago, Luigi Formisano, Dejan Juric, et al.
Breast Cancer Research : BCR|December 1, 2020
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastasesJose Pablo Leone, Kyrre E Emblem, Michelle Weitz, et al.
Pageof 3